lucentis造句
- A similar drug, Lucentis, was later approved for treating macular degeneration.
- In 2010 the US FDA approved the use of Lucentis intravitreal injections for macular edema.
- One agreement is for Lucentis; the other is for Xolair, both of which Novartis markets outside the US.
- Lucentis is one of several drugs called vascular endothelial growth factor ( VEGF ) inhibitors that can block the growth of abnormal blood vessels.
- Ranibizumab was developed by Genentech and is marketed in the United States by Genentech and elsewhere by Novartis, under the brand name Lucentis.
- Genentech has a drug, Lucentis, in late-stage trials, but analysts do not expect it to be on the market before 2006 or 2007.
- Genentech's celebrated new cancer drug, Avastin, also blocks VEGF to starve tumors of their drug supply, and Lucentis is a derivative of Avastin.
- In July 2005, Dr . Miller presented data from the ranibizumab ( Lucentis ) at the 23rd Annual Meeting of the American Society of Retina Specialists ( ASRS ) in Montreal, Quebec, Canada.
- In June 2007, Genentech began the construction and development of an " E . coli " manufacturing facility, also in Singapore, for the worldwide production of Lucentis ( ranibizumab injection ) bulk drug substance.
- Lucentis has a similar but smaller molecular structure to Avastin, and is FDA-approved ( 2006 ) for treating MacD, yet remains more costly, as is the more recent ( approved in 2011 ) EYLEA ( aflibercept ).
- It's difficult to see lucentis in a sentence. 用lucentis造句挺難的
- In Phase 2b studies, abicipar was shown to provide equal or potentially higher vision gains with fewer injections in patients with wet AMD ( wet age-related macular degeneration ), compared to standard anti-VEGF treatment with ranibizumab ( Lucentis ).
- A network of NEI supported researchers, who are a part of the Diabetic Retinopathy Clinical Research Network completed a two years study in 2015 that found the drug Lucentis can be an effective treatment for people with advanced stage diabetic retinopathy, called proliferative diabetic retinopathy.
- Hansen's designation comes from the genus " Sergia " and the Latin " lucentis " ( " lighting " ), likely referring to the sakura shrimp's phosphorescent photophores, though the sakura shrimp has not been observed to emit light.
- "' Ranibizumab "'( trade name "'Lucentis "'among others ) is a monoclonal antibody fragment ( anti-angiogenic that has been approved to treat the " wet " type of age-related macular degeneration ( AMD, also ARMD ), a common form of age-related vision loss.
- The Comparison of Age-Related Treatment Trial : Lucentis-Avastin ( CATT ) study was a two-year multicenter clinical trial that started in 2008 to compare the effectiveness of the two current treatments used for AMD . The results of the study concluded that both Lucentis and Avastin were equally effective in treating and improving vision, whether it was used monthly or on as needed basis.
- The Comparison of Age-Related Treatment Trial : Lucentis-Avastin ( CATT ) study was a two-year multicenter clinical trial that started in 2008 to compare the effectiveness of the two current treatments used for AMD . The results of the study concluded that both Lucentis and Avastin were equally effective in treating and improving vision, whether it was used monthly or on as needed basis.
- As of April 2015, there was a fierce debate in the UK and other European countries concerning the choice of prescribing bevacizumab or ranibizumab ( Lucentis ) for wet AMD . In the UK, part of the tension was between on the one hand, both the European Medicines Agency and the Medicines and Healthcare Products Regulatory Agency which had approved Lucentis but not Avastin for wet AMD, and their interest in ensuring that doctors to do not use medicines off-label when there are other, approved medications for the same indication, and on the other hand, NICE in the UK, which sets treatment guidelines, and has been unable so far to appraise Avastin as a first-line treatment, in order to save money for the National Health Service.
- As of April 2015, there was a fierce debate in the UK and other European countries concerning the choice of prescribing bevacizumab or ranibizumab ( Lucentis ) for wet AMD . In the UK, part of the tension was between on the one hand, both the European Medicines Agency and the Medicines and Healthcare Products Regulatory Agency which had approved Lucentis but not Avastin for wet AMD, and their interest in ensuring that doctors to do not use medicines off-label when there are other, approved medications for the same indication, and on the other hand, NICE in the UK, which sets treatment guidelines, and has been unable so far to appraise Avastin as a first-line treatment, in order to save money for the National Health Service.
手機版